Tag Archive for: Sanofi

Kling Bio Announces Collaboration with Sanofi for Accelerated Discovery of Neutralizing Antibodies

/in

Leverages Kling’s technology to discover hard-to-find, immuno-functional antibodies from immortalized human B cells Accelerating discovery of first-in-class antibodies to transform disease prevention and treatment Amsterdam, NLD – 24 July 2025 – Kling Bio (“Kling” or “the Company”), a biotech company developing antibody-based drugs for cancer and infectious diseases, today announced it has entered into a […]

Read more

Sanofi to acquire next-generation vaccine biotech Vicebio for US$1.6 billion

/in

Sanofi will gain access to Molecular Clamp technology that enables development of next-generation multivalent vaccines against respiratory pathogens and beyond Lead asset VXB-241 is a bivalent vaccine targeting Respiratory Syncytial Virus (RSV) and Human Metapneumovirus (hMPV), currently in exploratory Phase 1 Upfront payment of US$1.15 billion and milestones up to US$450 million London, UK, 22 […]

Read more

Neuraxpharm announces closing of acquisition of established products from Sanofi

/in

Düsseldorf and Barcelona – February 1, 2023 – Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, announces the closing of the previously announced acquisition of two established product portfolios for CNS disorders, pain and vascular diseases from Sanofi. Read more…

Read more

Sanofi offers to acquire Kiadis for €308 million

/in

Congratulations to Kiadis Pharma on recently announcing that it is being acquired by Sanofi in a deal valued at approximately €308m ($359m), a 272% premium over last week’s closing price, one of the largest premiums in European biotech. After the discontinuation of its lead product candidate and subsequent reorganization in 2019, Kiadis started 2020 as an entirely new company […]

Read more